Linezolid resistant Staphylococcus haemolyticus: First case report from India  by Gupta, Varsha et al.
837Asian Pacific Journal of Tropical Medicine (2012)837-838
Document heading          doi:  
Linezolid resistant Staphylococcus haemolyticus: First case report from India
Varsha Gupta1, Shivani Garg1, Ruby Jain1, Sudhir Garg2, Jagdish Chander1
1Department of Microbiology, Government Medical College Hospital, Sector 32, Chandigarh – 160030, India
2Department of Orthopedics, Government Medical College Hospital, Sector 32, Chandigarh- 160030, India
 Contents lists available at ScienceDirect
Asian Pacific Journal of Tropical Medicine
journal homepage:www.elsevier.com/locate/apjtm
ARTICLE INFO                           ABSTRACT
Article history:
Received 24 February 2012
Received in revised form 31 March 2012
Accepted 5 Apirl 2012
Available online 20 October 2012
Keywords:
Linezolid
Staphylococcus haemolyticus
Drug resistance
  *Corresponding author:  Dr.  Varsha Gupta,  Professor ,  Department  of 
Microbiology,Government Medical College Hospital, Sector 32, Chandigarh, India - 
160030.
      E-mail: varshagupta_99@yahoo.com
1. Introduction
  Linezolid is the first oxazolidinone antibiotic to be 
licensed for treatment of infections caused by gram-
positive bacteria with potent activity against methicillin-
resistant Staphylococcus aureus (S. aureus) (MRSA), 
glycopeptide-intermediate S. aureus (GISA) and vancomycin 
resistant enterococci (VRE)[1]. Linezolid acts by binding to 
the 50S subunit of the bacterial ribosome via interaction 
with the 23S rRNA hereby blocking an early step in 
protein synthesis[2]. The most frequent mutation, which 
is known to cause resistance to linezolid, is G2576T[3]. 
This mechanism of resistance has been documented in 
S. aureus[3]. Similar mechanism has been observed in 
Staphylococcus epidermidis (S. epidermidis)[4,5]. Recently 
cfr gene[6], which resides in a potentially mobile genetic 
element, has been shown to confer linezolid resistance to 
S. aureus and coagulase negative Staphylococci[7,8]. From 
India, reports of linezolid resistance have been documented 
in Staphylococcus cohnii(S. cohnii), Staphylococcus kloosii
(S. kloosii) from Kashmir and Staphylococcus hominis, 
Staphylococcus lugdunensis(S. lugdunensis) from Andhra 
Pradesh[9,10]. However, till date there is no report of 
resistance in Staphylococcus haemolyticus(S. haemolyticus) 
from India.
2. Case report 
  A 61 year old male patient had a history of fall one 
year back. He was admitted in a private hospital in 
Yamunanagar, Haryana. On examination he was found to 
have left sided fracture of the hip joint. The fracture was 
fixed with a plate but later on it was observed that there 
was non-union of the fracture and hence the plate was 
removed. There was oozing of pus from the surgical site. 
He was started on empirical treatment with linezolid and 
a combination of  amoxicillin and clavulanic acid. There 
was no response to the treatment. Thereafter he presented 
to the Orthopaedics Outpatient Department of GMCH, 
Chandigarh with persistent drainage of pus from the same 
surgical site. The pus sample was sent to the Department of 
Microbiology for culture and antibiotic sensitivity testing. 
The pus sample showed growth of coagulase-negative 
Staphylococcus after overnight incubation. The isolate was 
characterized phenotypically as S. haemolyticus based 
on slide and tube coagulase tests, urease test, ornithine 
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decarboxylase test,aerobic acid from mannose,novobiocin 
susceptibility and the test for acetoin production[11]. The 
species confirmation as S. haemolyticus was further done 
by using MicroScan Walkaway Automated system(NEW). 
Antimicrobial sensitivity testing was done by the Kirby-
Bauer disc diffusion method in accordance with the CLSI 
guidelines[12]. The isolate showed sensitivity to teicoplanin 
and clindamycin but was resistant to penicillin, oxacillin, 
erythromycin,  cotrimoxazole and linezolid. Minimum 
inhibitory concentration (MIC) was determined for linezolid, 
vancomycin, oxacillin, rifampin and teicoplanin by the E-test. 
The isolate was resistant to linezolid (MIC≥64 毺g/mL)
so it was discontinued and the patient was started on a 
combination of clindamycin and rifampin. The patient 
responded well to the above treatment and the surgical site 
healed. For further management of the fracture the patient 
was still visiting orthopaedic clinic.
3. Discussion  
  Multidrug resistant coagulase-negative Staphylococcus 
species (CoNS) are becoming the common causes of mortality 
and morbidity mainly in hospital settings. Emergence of 
resistance of these organisms to an increasing number of 
antibiotics has become a real concern. For such infections, 
antimicrobials like linezolid and glycopeptides are the 
alternative therapeutic agents. But if resistance develops to 
these antimicrobials also then the clinicians will be left with 
no therapeutic options. Coagulase negative Staphylococci 
have been reported to be important pathogens in patients 
with implants in orthopaedic practice[13].
  Regarding the mechanism of resistance to linezolid, it is 
principally associated with distinct nucleotide substitutions 
in domain V of the 23S rRNA gene, arising in at least two 
copies of the rRNA operons, with a stepwise increase due 
to successive accumulation of single point mutations. Post-
transcriptional methylation of A2503 in the 23S rRNA by 
the horizontally transferred cfr gene recently described 
in clinical isolates and derived from Staphylococci of 
animal origin has caused concern about the possible 
high transmission of linezolid resistance among clinical 
isolates[14]. Presently we do not have facilities to determine 
the exact mechanism of resistance.
  The present case is the first case of a linezolid resistant
S. haemolyticus from India in orthopaedic practice. The 
patient however responded to clindamycin and rifampin 
therapy after the removal of the plate.
  Since these days there is an increasing trend of the use 
of linezolid for treating gram-positive organisms hence 
microbiologists should be cautious in reporting the 
antimicrobial sensitivity of the methicillin resistant isolates 
to the clinicians so as to prevent the injudicious use of this 
therapeutic agent.
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